JENTADUETO XR Drug Patent Profile

« Back to Dashboard

Which patents cover Jentadueto Xr, and what generic alternatives are available?

Jentadueto Xr is a drug marketed by Boehringer Ingelheim and is included in one NDA. There are ten patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in JENTADUETO XR is linagliptin; metformin hydrochloride. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the linagliptin; metformin hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Jentadueto Xr

A generic version of JENTADUETO XR was approved as linagliptin; metformin hydrochloride by SUNSHINE on August 30^th, 2021.

Summary for JENTADUETO XR

US Patents:	10
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	6
Clinical Trials:	1
Drug Prices:	Drug price information for JENTADUETO XR
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for JENTADUETO XR
What excipients (inactive ingredients) are in JENTADUETO XR?	JENTADUETO XR excipients list
DailyMed Link:	JENTADUETO XR at DailyMed

See drug prices for JENTADUETO XR

Recent Clinical Trials for JENTADUETO XR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Boehringer Ingelheim	Phase 1

See all JENTADUETO XR clinical trials

Pharmacology for JENTADUETO XR

Drug Class	Biguanide Dipeptidyl Peptidase 4 Inhibitor
Mechanism of Action	Dipeptidyl Peptidase 4 Inhibitors

Paragraph IV (Patent) Challenges for JENTADUETO XR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
JENTADUETO XR	Extended-release Tablets	linagliptin; metformin hydrochloride	2.5 mg/1000 mg 5 mg/1000 mg	208026	1	2018-03-28

US Patents and Regulatory Information for JENTADUETO XR

JENTADUETO XR is protected by ten US patents and two FDA Regulatory Exclusivities.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Boehringer Ingelheim	JENTADUETO XR	linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208026-001	May 27, 2016		RX	Yes	No	11,911,388
Boehringer Ingelheim	JENTADUETO XR	linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208026-002	May 27, 2016		RX	Yes	Yes	9,173,859*PED				Y
Boehringer Ingelheim	JENTADUETO XR	linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208026-002	May 27, 2016		RX	Yes	Yes
Boehringer Ingelheim	JENTADUETO XR	linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208026-001	May 27, 2016		RX	Yes	No	8,673,927*PED				Y

Expired US Patents for JENTADUETO XR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Boehringer Ingelheim	JENTADUETO XR	linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208026-002	May 27, 2016	8,178,541
Boehringer Ingelheim	JENTADUETO XR	linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208026-002	May 27, 2016	6,488,962
Boehringer Ingelheim	JENTADUETO XR	linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208026-002	May 27, 2016	6,635,280
Boehringer Ingelheim	JENTADUETO XR	linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208026-001	May 27, 2016	6,635,280

EU/EMA Drug Approvals for JENTADUETO XR

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Boehringer Ingelheim International GmbH	Jentadueto	linagliptin, metformin hydrochloride	EMEA/H/C/002279Treatment of adult patients with type-2 diabetes mellitus:Jentadueto is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients inadequately controlled on their maximal tolerated dose of metformin alone, or those already being treated with the combination of linagliptin and metformin.Jentadueto is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.	Authorised	no	no	no	2012-07-19

International Patents for JENTADUETO XR

When does loss-of-exclusivity occur for JENTADUETO XR?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Canada

Chile

China

Eurasian Patent Organization

European Patent Office

Hong Kong

India

Japan

Mexico

Philippines

Singapore

South Korea

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering JENTADUETO XR around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	071175
Australia	2009232043
Brazil	PI0911273
Canada	2720450

Supplementary Protection Certificates for JENTADUETO XR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1532149	C300504	Netherlands		PRODUCT NAME: LINAGLIPTINE, DESGEWENST IN DE VORM VAN ZOUT; REGISTRATION NO/DATE: EU/1/11/707/001-011 20110824
1532149	1190035-4	Sweden		PERIOD OF VALIDITY (FROM - UNTIL): 20230819 - 20260829
1532149	PA2011013	Lithuania		PRODUCT NAME: LINAGLIPTINUM; REGISTRATION NO/DATE: EU/1/11/707/001, 2011 08 24 EU/1/11/707/002, 2011 08 24 EU/1/11/707/003, 2011 08 24 EU/1/11/707/004, 2011 08 24 EU/1/11/707/005, 2011 08 24 EU/1/11/707/006, 2011 08 24 EU/1/11/707/007, 2011 08 24 EU/1/11/707/008, 2011 08 24 EU/1/11/707/00 2011082
1532149	C20110018 00046	Estonia		PRODUCT NAME: TRAJENTA-LINAGLIPTIN; REG NO/DATE: FINAL 24.08.2011

Jentadueto XR Market Dynamics, Patent Position, and Financial Trajectory

Last updated: October 27, 2026

Jentadueto XR is a fixed-dose combination of linagliptin and extended-release metformin for adults with type 2 diabetes. Its commercial position has weakened as diabetes treatment shifted toward GLP-1 receptor agonists and SGLT2 inhibitors, while linagliptin faced mature-market pressure and metformin remained generic. Boehringer Ingelheim and Eli Lilly do not report Jentadueto XR revenue separately, so the product’s financial trajectory must be inferred from the broader Tradjenta and diabetes portfolios rather than a standalone sales line.

What is Jentadueto XR and how does it work?

Jentadueto XR combines two established mechanisms:

Component	Mechanism	Commercial status
Linagliptin	DPP-4 inhibition, increasing incretin activity and glucose-dependent insulin secretion	Branded and mature
Metformin hydrochloride ER	Reduces hepatic glucose production and improves insulin sensitivity	Generic and highly competitive

The product is used with diet and exercise to improve glycemic control in adults with type 2 diabetes. It is not indicated for type 1 diabetes or diabetic ketoacidosis. The combination is available in once-daily extended-release strengths that pair linagliptin with different metformin doses. The FDA label identifies Jentadueto XR as an oral treatment, with dosing based on prior metformin exposure and renal function.[1]

Jentadueto XR’s principal clinical value is convenience. Patients already receiving linagliptin and extended-release metformin can reduce pill burden through a single tablet. Its commercial limitation is that the product does not provide the cardiovascular, renal, or weight-loss profile increasingly demanded by prescribers and payers.

When was Jentadueto XR approved by the FDA?

Jentadueto XR was approved through an FDA new drug application for the fixed-dose combination of linagliptin and extended-release metformin. The immediate-release Jentadueto product received an earlier U.S. approval, followed by the extended-release version.[1][2]

FDA milestone	Product	Significance
2011	Tradjenta, linagliptin	U.S. approval of the DPP-4 inhibitor component
2012	Jentadueto, linagliptin/metformin immediate release	Initial fixed-dose combination
2012	Jentadueto XR, linagliptin/metformin extended release	Once-daily extended-release combination
Current regulatory framework	NDA product	Remains subject to FDA labeling, safety, and manufacturing requirements

Jentadueto XR is a small-molecule prescription product, not a biologic. Biosimilar substitution rules therefore do not apply. Competitive entry occurs through the abbreviated new drug application pathway for generics.

What is the Orange Book status of Jentadueto XR?

The FDA Orange Book identifies approved drug products, therapeutic equivalence information, and patent or exclusivity entries submitted by the NDA holder.[2] Jentadueto XR’s relevant regulatory protection has historically been based on a combination of:

1. Linagliptin compound protection.
2. Combination-product claims covering linagliptin with metformin.
3. Extended-release formulation claims.
4. Method-of-use claims associated with treatment of type 2 diabetes.

The core compound protection for linagliptin has reached or passed the end of its primary U.S. term, subject to the specific patent, pediatric extension, and Orange Book listing. That change materially reduces the strategic value of the branded product because a generic manufacturer can challenge or design around remaining formulation and combination claims.

A product-specific patent expiration date should not be treated as a single date without reviewing the current Orange Book patent table. Different listed patents can have different expiration dates, and pediatric exclusivity can extend certain protections by six months. FDA Orange Book status also does not prove that a generic has received final approval or launched commercially.[2]

What patents protect Jentadueto XR?

The Jentadueto XR estate is narrower than the estate surrounding a new molecular entity. Metformin is a long-generic drug, so the main patent value lies in linagliptin, the fixed-dose combination, and the extended-release dosage form.

Core compound patents

Linagliptin was discovered and developed through the Boehringer Ingelheim and Eli Lilly diabetes alliance. Compound patents provided the strongest early exclusivity because they covered the active pharmaceutical ingredient across multiple formulations and indications. As those patents expired, the estate shifted toward formulation and combination claims.

Combination patents

Combination patents may cover the use of linagliptin with metformin, including specific dosage relationships or treatment regimens. Their value depends on claim scope and whether an ANDA applicant can avoid infringement through a different strength, dosing instruction, or formulation.

Extended-release formulation patents

Jentadueto XR’s commercial differentiation depends on the extended-release delivery system. Formulation patents may cover:

• The matrix or release-control technology.
• Specific ratios of linagliptin and metformin.
• Release profiles.
• Tablet composition and manufacturing parameters.
• Dose combinations and once-daily administration.

Formulation patents generally provide weaker protection than a compound patent because generic applicants can attempt a non-infringing formulation. The practical strength of these patents depends on claim breadth, prosecution history, written-description support, and whether the formulation is difficult to replicate at commercial scale.

When does Jentadueto XR lose exclusivity?

Jentadueto XR loses exclusivity in stages rather than on one universal date.

Protection layer	Strategic effect
New chemical entity or compound protection	Blocks products containing linagliptin
Fixed-dose combination protection	Targets linagliptin/metformin combinations
Extended-release formulation protection	Targets once-daily formulation designs
Pediatric exclusivity	Can add six months to eligible patent or regulatory protection
Regulatory exclusivity	Controls certain FDA approval timing independently of patents

The principal commercial inflection point is the end of linagliptin’s strongest compound protection. After that point, generic manufacturers can pursue linagliptin-containing products, subject to any enforceable formulation or combination patents.

A Paragraph IV certification can accelerate litigation. An ANDA applicant uses Paragraph IV to assert that a listed patent is invalid, unenforceable, or not infringed. The NDA holder generally has 45 days to file an infringement action after receiving notice. A timely suit can trigger a 30-month stay of FDA approval, although the stay can end earlier under statutory conditions.[3]

Which companies are challenging Jentadueto XR?

Public commercial pressure comes from several directions:

• Generic metformin manufacturers, which make the metformin component inexpensive.
• Generic DPP-4 inhibitor manufacturers, where approved products become available.
• Other branded DPP-4 inhibitors, including sitagliptin and saxagliptin.
• GLP-1 receptor agonists, including semaglutide, dulaglutide, and tirzepatide.
• SGLT2 inhibitors, including empagliflozin and dapagliflozin.

A specific ANDA challenger should be confirmed through current FDA Orange Book records and federal court filings. The absence of a prominent reported Paragraph IV case does not eliminate generic risk. A company may file an ANDA with Paragraph III certification, use a different formulation, or delay commercial launch until patent risk declines.

What is the competitive position of Jentadueto XR?

Jentadueto XR competes in a treatment segment that has become less attractive relative to newer diabetes medicines.

Product class	Main advantage over Jentadueto XR	Main limitation
GLP-1 receptor agonists	Greater weight loss and strong glucose lowering	Injectable or premium oral products; higher cost
SGLT2 inhibitors	Cardiovascular and renal outcome advantages for selected patients	Genitourinary adverse effects and renal limitations
Other DPP-4 inhibitors	Familiar oral treatment and payer competition	Similar efficacy and declining class growth
Metformin combinations	Low cost and established use	Limited differentiation
Insulin	Strong glucose-lowering capability	Hypoglycemia, weight gain, injection burden

Jentadueto XR retains a role for patients who need an oral, weight-neutral treatment and are already appropriate for metformin and linagliptin. Its value is higher when formulary access, tolerability, and adherence matter more than weight loss or cardiorenal outcomes.

The largest strategic disadvantage is clinical differentiation. DPP-4 inhibitors generally have modest glucose-lowering efficacy and are weight neutral. They do not compete effectively with GLP-1 and GIP/GLP-1 therapies on weight reduction, while SGLT2 inhibitors provide outcomes data that can influence treatment guidelines and payer protocols.

What is the financial trajectory for Jentadueto XR?

Boehringer Ingelheim and Eli Lilly do not provide a separate public revenue line for Jentadueto XR. Reported financial data generally aggregate the product with Tradjenta, diabetes products, alliance revenue, or broader human-pharma categories. This prevents a reliable standalone revenue series.

The product’s financial trajectory is nevertheless clear:

Launch and growth phase

Jentadueto XR benefited from the commercial infrastructure supporting Tradjenta. The fixed-dose combination offered a convenient extension of the linagliptin franchise and allowed the companies to defend branded prescriptions against separate generic metformin use.

Mature-brand phase

As metformin became fully commoditized and DPP-4 competition increased, Jentadueto XR’s pricing power weakened. Rebate demands from pharmacy benefit managers increased, particularly where sitagliptin or other DPP-4 products were available under preferred formulary terms.

Decline phase

The diabetes market shifted toward higher-growth products with weight-loss and cardiorenal benefits. GLP-1 receptor agonists and SGLT2 inhibitors captured physician attention, payer budgets, and corporate investment. Jentadueto XR became a maintenance product rather than a growth driver.

Financial exposure

The product’s direct revenue exposure is likely modest relative to newer products in the Boehringer-Lilly diabetes portfolio. Jardiance has become the central commercial asset of that alliance, while Tradjenta and Jentadueto represent older DPP-4 revenue streams. Corporate reports from both companies emphasize portfolio-level performance and do not isolate Jentadueto XR sales.[4][5]

Financial driver	Effect on Jentadueto XR
Generic metformin	Reduces combination-product differentiation
DPP-4 class competition	Compresses price and share
GLP-1 adoption	Reduces use in patients seeking weight loss
SGLT2 outcome data	Diverts guideline-driven prescribing
Formulary rebates	Reduces net price
Fixed-dose convenience	Supports adherence and residual demand
Patent expiry	Increases generic-entry risk

What generic launch scenarios exist for Jentadueto XR?

Three scenarios are commercially relevant.

Scenario 1: Delayed generic entry

Generic approval is delayed by unresolved formulation patents, regulatory deficiencies, manufacturing issues, or the absence of a commercially attractive ANDA opportunity. Branded sales decline gradually through formulary pressure but remain protected from direct substitution.

Scenario 2: Limited generic entry

One or more generic products launch with restricted strengths or limited distribution. Branded Jentadueto XR retains some patients because of physician familiarity, copay programs, or payer contracts.

Scenario 3: Broad generic substitution

Multiple ANDA-approved products reach the market after patent barriers expire or are removed. Pharmacy-level substitution causes rapid volume migration and steep net-price erosion. In this scenario, the brand’s remaining value is primarily tied to residual prescriptions, supply reliability, and patient persistence.

The most likely long-term direction is continued erosion rather than a sudden return to growth. A generic launch would accelerate that decline but would not create the underlying pressure, which is already driven by therapeutic substitution and payer economics.

How strong is the Jentadueto XR patent estate?

The estate is moderate to weak from a lifecycle-management perspective.

Its strengths are:

• The product combines a recognized active ingredient with a convenient extended-release formulation.
• Formulation patents can delay direct substitution even after compound protection ends.
• Manufacturing complexity may make exact replication more difficult than generic metformin production.

Its weaknesses are:

• Metformin has no meaningful residual exclusivity.
• Linagliptin’s primary compound protection has matured.
• Formulation claims are more vulnerable to design-around strategies.
• The DPP-4 class faces clinical and commercial substitution.
• There is no biologic manufacturing barrier.
• The product has limited differentiation from separate tablets.

The estate can support a period of residual branded demand, but it is unlikely to sustain premium pricing against multiple generic competitors.

What licensing deals affect Jentadueto XR?

Jentadueto XR was developed under the Boehringer Ingelheim-Eli Lilly diabetes alliance. The alliance covers development, commercialization, and economic sharing across diabetes products, including linagliptin-based products and empagliflozin-based products.[4][5]

The strategic importance of the agreement has shifted. Early in the product lifecycle, shared commercialization reduced launch costs and expanded geographic reach. At maturity, the alliance primarily affects accounting, profit allocation, supply responsibilities, and portfolio prioritization. The partnership does not remove generic or therapeutic-substitution risk.

What litigation affects Jentadueto XR?

The principal legal risks are expected to involve:

• Paragraph IV challenges to listed patents.
• Patent-infringement litigation over extended-release formulations.
• ANDA disputes involving dosage strengths or release profiles.
• Patent-term and pediatric-exclusivity interpretation.
• Product-liability or labeling claims, although these are distinct from market-exclusivity litigation.

No litigation outcome should be inferred solely from Orange Book listings. Patent litigation status must be established through federal court dockets, FDA records, and company disclosures. A patent can remain listed while being invalidated, disclaimed, licensed, or commercially irrelevant.

What is the outlook for Jentadueto XR?

Jentadueto XR is a mature branded diabetes product with declining strategic importance. Its remaining commercial value rests on oral convenience, weight neutrality, physician familiarity, and access for patients who do not require a GLP-1 receptor agonist or SGLT2 inhibitor.

The product is unlikely to regain material growth without a major change in pricing, formulary positioning, or clinical use. The highest-probability trajectory is stable-to-declining volume followed by accelerated erosion when broad generic competition becomes commercially available.

Key Takeaways

• Jentadueto XR combines linagliptin with extended-release metformin for type 2 diabetes.
• The product’s strongest protection was tied to linagliptin compound patents; remaining value depends more on formulation and combination claims.
• Boehringer Ingelheim and Eli Lilly do not disclose standalone Jentadueto XR revenue.
• Financial performance is pressured by generic metformin, mature DPP-4 competition, GLP-1 adoption, and SGLT2 outcome advantages.
• Biosimilar risk is not relevant because Jentadueto XR is a small-molecule product.
• Paragraph IV litigation and generic-entry timing depend on the current Orange Book listings and individual ANDA certifications.
• The product’s patent estate is less durable than the estate for a new molecular entity or biologic.
• The commercial outlook is mature to declining, with residual demand concentrated among patients seeking an oral, weight-neutral regimen.

FAQs

Is Jentadueto XR the same as Tradjenta?

No. Tradjenta contains linagliptin alone. Jentadueto XR combines linagliptin with extended-release metformin.

Can Jentadueto XR be substituted with separate tablets?

Clinically, a prescriber may use separate linagliptin and extended-release metformin tablets, but the specific substitution must reflect dose, renal function, tolerability, and payer coverage.

Does Jentadueto XR cause weight loss?

Weight loss is not a defining benefit. Linagliptin is generally weight neutral, while metformin may have a modest favorable weight effect.

Is Jentadueto XR protected by orphan-drug exclusivity?

No. Jentadueto XR is indicated for the common metabolic disease type 2 diabetes and does not rely on orphan-drug exclusivity.

Why is Jentadueto XR less commercially attractive than newer diabetes drugs?

It has limited differentiation on weight reduction and cardiovascular or renal outcomes. Newer GLP-1 and SGLT2 therapies command greater clinical and payer attention in appropriate patient populations.

References

1. U.S. Food and Drug Administration. (n.d.). Jentadueto XR: Prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j).
4. Boehringer Ingelheim. (2024). Annual report and financial information.
5. Eli Lilly and Company. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.